Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.47 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8380051 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL29892 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL35541 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL1452757 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL3457992 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL15229292 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL2906298 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL2903635 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL19579380 | 0.98 | ATM (0.63) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL6465406 | 0.98 | ATM (0.63) | HCAR2ATMNAAAAPPTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 521 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717744-A1 | USE OF A COMPOSITION BASED ON CYANOACRYLATE AND (METH)ACRYLATE | Bostik SA (FR) | 2026-04-01 | — | — | EP | claimed |
| US-20260060402-A1 | REMOVABLE NAIL COATINGS AND COMPOSITIONS AND METHODS OF PREPARING THEREOF | LIQWD INC (US) | 2026-03-05 | — | — | US | claimed |
| EP-3852815-B1 | STABLE COMPOSITIONS COMPOSED OF A RADIOPAQUE AGENT AND CYANOACRYLATE MONOMER AND APPLICATIONS THEREOF | CHEMENCE MEDICAL INC (US) | 2026-02-25 | — | — | EP | claimed |
| US-20260041183-A1 | ADHESIVE FOR COSMETIC ARTICLE AND METHOD OF FORMING | FULLER H B CO (US) | 2026-02-12 | — | — | US | claimed |
| EP-4212106-B1 | HANDHELD DEVICE FOR APPLYING A CYANOACRYLATE ADHESIVE COMPOSITION | CUANTUM MEDICAL COSMETICS S L (ES) | 2025-11-12 | — | — | EP | claimed |
| US-20250215132-A1 | TWO-PART CURABLE COMPOSITION | BOSTIK SA (FR) | 2025-07-03 | — | — | US | claimed |
| EP-3579890-B1 | METHODS AND COMPOSITIONS COMPRISING BIODEGRADABLE CYANOACRYLATES | FEMASYS INC (US) | 2025-06-18 | — | — | EP | claimed |
| CN-119455136-A | Biodegradable stent, preparation method thereof and biodegradable stent system | 上海畅德医疗科技有限公司 | 2025-02-18 | — | — | CN | claimed |
| EP-4504844-A1 | TWO-PART CURABLE COMPOSITION | Bostik SA (FR) | 2025-02-12 | — | — | EP | claimed |
| US-20240240064-A1 | TWO-PART CURABLE COMPOSITION | BOSTIK SA (FR) | 2024-07-18 | — | — | US | claimed |
| US-20030082116-A1 | Adhesive compositions containing dual function stabilizers and active agents | CLOSURE MEDICAL CORPORATION (US) | 2003-05-01 | — | — | US | claimed |
| EP-1283707-A1 | POLYMERIZABLE COMPOSITIONS AND METHODS OF USE | Provasis Therapeutics, Inc. (US) | 2003-02-19 | — | — | EP | claimed |
| WO-2002053666-A1 | CYANOACRYLATE COMPOSITIONS CURABLE TO FLEXIBLE POLYMERIC MATERIALS | LOCTITE (R & D) LIMITED (IE) | 2002-07-11 | — | — | WO | claimed |
| WO-2002020069-A2 | ANTIOXIDANT ENRICHED ADHESIVE COMPOSITIONS AND STORAGE CONTAINERS THEREFOR | CLOSURE MEDICAL CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| US-20020018752-A1 | Polymerizable compositions and methods of use | STRYKER EUROPEAN HOLDINGS III, LLC | 2002-02-14 | — | — | US | claimed |
| WO-2001089501-A1 | POLYMERIZABLE COMPOSITIONS AND METHODS OF USE | PROVASIS THERAPEUTICS, INC. (US) | 2001-11-29 | — | — | WO | claimed |
| EP-1100380-A1 | BIOABSORBABLE BLENDS AND SURGICAL ARTICLES THEREFROM | TYCO HEALTHCARE GROUP LP (US) | 2001-05-23 | — | — | EP | claimed |
| WO-2000072761-A1 | BIOABSORBABLE BLENDS AND SURGICAL ARTICLES THEREFROM | TYCO HEALTH CARE GROUP, LP (US) | 2000-12-07 | — | — | WO | claimed |
| EP-0441468-B1 | Gas-containing microparticles composed of polyaldehydes as contrast agents | SCHERING AG (DE) | 1996-09-11 | — | — | EP | claimed |
| US-5501863-A | Contrast media synthesized from polyaldehydes | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-03-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060402-A1 | REMOVABLE NAIL COATINGS AND COMPOSITIONS AND METHODS OF PREPARING THEREOF | POLR1C, PRKDC, PIK3C3 | HCAR2 4722/4885ATM 2853/4885NAAA 3037/4885 |
| US-20260041183-A1 | ADHESIVE FOR COSMETIC ARTICLE AND METHOD OF FORMING | KRT18, CDH1, CFL1 | HCAR2 3987/4885ATM 2463/4885NAAA 2705/4885 |
| US-20030082116-A1 | Adhesive compositions containing dual function stabilizers and active agents | TLN1, PTK2, ILK | HCAR2 2985/4885ATM 2978/4885NAAA 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.